Credit Suisse Group cut shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to a hold rating in a research note issued to investors on Friday. The firm currently has $485.00 target price on the biopharmaceutical company’s stock.
REGN has been the subject of several other reports. Oppenheimer Holdings, Inc. started coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, March 16th. They set a hold rating for the company. Vetr downgraded shares of Regeneron Pharmaceuticals from a sell rating to a strong sell rating and set a $368.84 price target for the company. in a report on Monday, May 15th. Leerink Swann set a $448.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, March 28th. BTIG Research restated a buy rating and issued a $460.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, March 29th. Finally, Robert W. Baird restated a neutral rating and issued a $369.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 28th. One equities research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $457.83.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.34% on Friday, reaching $498.11. 620,273 shares of the company’s stock traded hands. The stock has a market capitalization of $52.59 billion, a PE ratio of 60.30 and a beta of 1.67. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55. The firm’s 50-day moving average is $474.83 and its 200 day moving average is $400.97.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.30 billion. During the same period last year, the firm posted $2.57 EPS. The firm’s quarterly revenue was up 9.8% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals will post $12.73 EPS for the current year.
In other news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $482.55, for a total value of $482,550.00. Following the sale, the director now owns 14,000 shares of the company’s stock, valued at $6,755,700. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Michael S. Aberman sold 2,269 shares of the business’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the completion of the sale, the senior vice president now directly owns 9,193 shares in the company, valued at approximately $4,894,537.06. The disclosure for this sale can be found here. In the last three months, insiders sold 59,396 shares of company stock worth $28,484,734. 10.40% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the company. Korea Investment CORP raised its stake in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares in the last quarter. FNY Managed Accounts LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $140,000. Alpha Windward LLC raised its stake in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 16 shares in the last quarter. Welch & Forbes LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $211,000. Finally, Comerica Securities Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $213,000. 66.87% of the stock is currently owned by institutional investors and hedge funds.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.